Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial

por Sierra, Jorge, Montesinos, Pau, Thomas, Xavier, Griskevicius, Laimonas, Cluzeau, Thomas, Caillot, Denis, Legrand, Ollivier, Minotti, Clara, Luppi, Mario, Farkas, Firas, Bengoudifa, Bourras-Rezki, Gilotti, Geralyn, Hodzic, Sejla, Rambaldi, Alessandro, Venditti, Adriano
Publicado 2023

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

por Cervantes, Francisco, Ross, David M., Radinoff, Atanas, Palandri, Francesca, Myasnikov, Alexandr, Vannucchi, Alessandro M., Zachee, Pierre, Gisslinger, Heinz, Komatsu, Norio, Foltz, Lynda, Mannelli, Francesco, Passamonti, Francesco, Gilotti, Geralyn, Sadek, Islam, Tiwari, Ranjan, Zor, Evren, Al-Ali, Haifa Kathrin
Publicado 2021

Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

por Cervantes, Francisco, Ross, David M., Radinoff, Atanas, Palandri, Francesca, Myasnikov, Alexandr, Vannucchi, Alessandro M., Zachee, Pierre, Gisslinger, Heinz, Komatsu, Norio, Foltz, Lynda, Mannelli, Francesco, Passamonti, Francesco, Gilotti, Geralyn, Sadek, Islam, Tiwari, Ranjan, Zor, Evren, Al-Ali, Haifa Kathrin
Publicado 2021